{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:22:39Z","timestamp":1794090159138,"version":"4.8.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Migraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated. To support clinical decision-making, we convened a European panel of experts to develop a ten-step approach to the diagnosis and management of migraine. Each step was established by expert consensus and supported by a review of current literature, and the Consensus Statement is endorsed by the European Headache Federation and the European Academy of Neurology. In this Consensus Statement, we introduce typical clinical features, diagnostic criteria and differential diagnoses of migraine. We then emphasize the value of patient centricity and patient education to ensure treatment adherence and satisfaction with care provision. Further, we outline best practices for acute and preventive treatment of migraine in various patient populations, including adults, children and adolescents, pregnant and breastfeeding women, and older people. In addition, we provide recommendations for evaluating treatment response and managing treatment failure. Lastly, we discuss the management of complications and comorbidities as well as the importance of planning long-term follow-up.<\/jats:p>","DOI":"10.1038\/s41582-021-00509-5","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T06:03:33Z","timestamp":1623996213000},"page":"501-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":557,"title":["Diagnosis and management of migraine in ten steps"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-8971","authenticated-orcid":false,"given":"Anna K.","family":"Eigenbrodt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0953-5701","authenticated-orcid":false,"given":"Sabrina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-8612","authenticated-orcid":false,"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos D.","family":"Mitsikostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-5132","authenticated-orcid":false,"given":"Alexandra J.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-5013","authenticated-orcid":false,"given":"Anne","family":"Ducros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Lant\u00e9ri-Minet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3457-0242","authenticated-orcid":false,"given":"Mark","family":"Braschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita Sanchez","family":"del Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8232-9138","authenticated-orcid":false,"given":"Oved","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2797-2398","authenticated-orcid":false,"given":"Aynur","family":"\u00d6zge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayten","family":"Mammadbayli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3888-2630","authenticated-orcid":false,"given":"Mihails","family":"Arons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-9548","authenticated-orcid":false,"given":"Kirill","family":"Skorobogatykh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Romanenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela M.","family":"Terwindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-3899","authenticated-orcid":false,"given":"Koen","family":"Paemeleire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-1939","authenticated-orcid":false,"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-0725","authenticated-orcid":false,"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6262-2986","authenticated-orcid":false,"given":"Henrik W.","family":"Schytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9932-1159","authenticated-orcid":false,"given":"Zaza","family":"Katsarava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1882-4337","authenticated-orcid":false,"given":"Timothy J.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"509_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina, M. Migraine. N. Engl. J. Med. 383, 1866\u20131876 (2020).","journal-title":"N. Engl. J. Med."},{"key":"509_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBD 2016 Neurology Collaborators.","year":"2019","unstructured":"GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 459\u2013480 (2019).","journal-title":"Lancet Neurol."},{"key":"509_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators.","year":"2018","unstructured":"GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 954\u2013976 (2018).","journal-title":"Lancet Neurol."},{"key":"509_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"[No authors listed]","year":"2018","unstructured":"[No authors listed] Headache Classification Committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd edition. Cephalalgia 38, 1\u2013211 (2018).","journal-title":"Cephalalgia"},{"key":"509_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.1468-2982.1992.1204221.x","volume":"12","author":"BK Rasmussen","year":"1992","unstructured":"Rasmussen, B. K. & Olesen, J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 12, 221\u2013228 (1992).","journal-title":"Cephalalgia"},{"key":"509_CR6","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1212\/WNL.0b013e3182749eed","volume":"79","author":"JM Hansen","year":"2012","unstructured":"Hansen, J. M. et al. Migraine headache is present in the aura phase. Neurology 79, 2044\u20132049 (2012).","journal-title":"Neurology"},{"key":"509_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","volume":"30","author":"JL Natoli","year":"2010","unstructured":"Natoli, J. L. et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 30, 599\u2013609 (2010).","journal-title":"Cephalalgia"},{"key":"509_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina, M. et al. Migraine and the trigeminovascular system\u201340 years and counting. Lancet Neurol. 18, 795\u2013804 (2019).","journal-title":"Lancet Neurol."},{"key":"509_CR9","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina, M. et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397, 1496\u20131504 (2021).","journal-title":"Lancet"},{"key":"509_CR10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina, M. et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397, 1505\u20131518 (2021).","journal-title":"Lancet"},{"key":"509_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava, Z., Mania, M., Lampl, C., Herberhold, J. & Steiner, T. J. Poor medical care for people with migraine in Europe \u2013 evidence from the Eurolight study. J. Headache Pain 19, 10 (2018).","journal-title":"J. Headache Pain"},{"key":"509_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina, M. et al. Migraine: epidemiology and systems of care. Lancet 397, 1485\u20131495 (2021).","journal-title":"Lancet"},{"key":"509_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/0895-4356(91)90147-2","volume":"44","author":"BK Rasmussen","year":"1991","unstructured":"Rasmussen, B. K., Jensen, R., Schroll, M. & Olesen, J. Epidemiology of headache in a general population\u2013a prevalence study. J. Clin. Epidemiol. 44, 1147\u20131157 (1991).","journal-title":"J. Clin. Epidemiol."},{"key":"509_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41582-018-0098-4","volume":"14","author":"N Karsan","year":"2018","unstructured":"Karsan, N. & Goadsby, P. J. Biological insights from the premonitory symptoms of migraine. Nat. Rev. Neurol. 14, 699\u2013710 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"509_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1212\/WNL.0000000000002789","volume":"87","author":"NJ Giffin","year":"2016","unstructured":"Giffin, N. J., Lipton, R. B., Silberstein, S. D., Olesen, J. & Goadsby, P. J. The migraine postdrome. Neurology 87, 309\u2013313 (2016).","journal-title":"Neurology"},{"key":"509_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/brain\/119.2.355","volume":"119","author":"MB Russell","year":"1996","unstructured":"Russell, M. B. & Olesen, J. A nosographic analysis of the migraine aura in a general population. Brain 119, 355\u2013361 (1996).","journal-title":"Brain"},{"key":"509_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano, D. et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J. Headache Pain 18, 101 (2017).","journal-title":"J. Headache Pain"},{"key":"509_CR18","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1212\/WNL.43.7.1369","volume":"43","author":"MB Russell","year":"1993","unstructured":"Russell, M. B., Hilden, J., S\u00f8rensen, S. A. & Olesen, J. Familial occurrence of migraine without aura and migraine with aura. Neurology 43, 1369\u20131373 (1993).","journal-title":"Neurology"},{"key":"509_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/1531-8249(199902)45:2<242::AID-ANA15>3.0.CO;2-1","volume":"45","author":"V Ulrich","year":"1999","unstructured":"Ulrich, V., Gervil, M., Kyvik, K. O., Olesen, J. & Russell, M. B. Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. Ann. Neurol. 45, 242\u2013246 (1999).","journal-title":"Ann. Neurol."},{"key":"509_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1046\/j.1468-2982.1996.1603156.x","volume":"16","author":"MB Russell","year":"1996","unstructured":"Russell, M. B., Fenger, K. & Olesen, J. The family history of migraine. Direct versus indirect information. Cephalalgia 16, 156\u2013160 (1996).","journal-title":"Cephalalgia"},{"key":"509_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-2982.2007.01239.x","volume":"27","author":"D Phillip","year":"2007","unstructured":"Phillip, D., Lyngberg, A. & Jensen, R. Assessment of headache diagnosis. A comparative population study of a clinical interview with a diagnostic headache diary. Cephalalgia 27, 1\u20138 (2007).","journal-title":"Cephalalgia"},{"key":"509_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/01.WNL.0000078940.53438.83","volume":"61","author":"RB Lipton","year":"2003","unstructured":"Lipton, R. B. et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 61, 375\u2013382 (2003).","journal-title":"Neurology"},{"key":"509_CR23","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/j.1526-4610.2005.00265.x","volume":"45","author":"MJA L\u00e1inez","year":"2005","unstructured":"L\u00e1inez, M. J. A. et al. Development and validation of the migraine screen questionnaire (MS-Q). Headache 45, 1328\u20131338 (2005).","journal-title":"Headache"},{"key":"509_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s10194-005-0189-7","volume":"6","author":"F Brighina","year":"2005","unstructured":"Brighina, F. et al. A validation study of an Italian version of the ID Migraine: preliminary results. J. Headache Pain 6, 216\u2013219 (2005).","journal-title":"J. Headache Pain"},{"key":"509_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1526-4610.2009.01449.x","volume":"50","author":"R Gil-Gouveia","year":"2010","unstructured":"Gil-Gouveia, R. & Martins, I. Validation of the Portuguese version of ID-Migraine. Headache 50, 396\u2013402 (2010).","journal-title":"Headache"},{"key":"509_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0938-z","volume":"19","author":"\u00c9 Cs\u00e9p\u00e1ny","year":"2018","unstructured":"Cs\u00e9p\u00e1ny, \u00c9. et al. The validation of the Hungarian version of the ID-migraine questionnaire. J. Headache Pain 19, 106 (2018).","journal-title":"J. Headache Pain"},{"key":"509_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5455\/medarh.2018.72.430-433","volume":"72","author":"D Delic","year":"2018","unstructured":"Delic, D. et al. Translation and transcultural validation of migraine screening questionnaire (MS-Q). Med. Arch. 72, 430\u2013433 (2018).","journal-title":"Med. Arch."},{"key":"509_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-021-00257-2","volume":"7","author":"S Ashina","year":"2021","unstructured":"Ashina, S. et al. Tension-type headache. Nat. Rev. Dis. Primers 7, 24 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"509_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1468-2982.2008.01592.x","volume":"28","author":"M Fischera","year":"2008","unstructured":"Fischera, M., Marziniak, M., Gralow, I. & Evers, S. The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia 28, 614\u2013618 (2008).","journal-title":"Cephalalgia"},{"key":"509_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","volume":"18","author":"H-C Diener","year":"2019","unstructured":"Diener, H.-C. et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 18, 891\u2013902 (2019).","journal-title":"Lancet Neurol."},{"key":"509_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1212\/WNL.0000000000006697","volume":"92","author":"TP Do","year":"2019","unstructured":"Do, T. P. et al. Red and orange flags for secondary headaches in clinical practice. Neurology 92, 134\u2013144 (2019).","journal-title":"Neurology"},{"key":"509_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner, T. J. et al. Aids to management of headache disorders in primary care (2nd edition). J. Headache Pain 20, 57 (2019).","journal-title":"J. Headache Pain"},{"key":"509_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0596-y","volume":"17","author":"DD Mitsikostas","year":"2015","unstructured":"Mitsikostas, D. D. et al. European Headache Federation consensus on technical investigation for primary headache disorders. J. Headache Pain 17, 5 (2015).","journal-title":"J. Headache Pain"},{"key":"509_CR34","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMra072149","volume":"357","author":"DJ Brenner","year":"2007","unstructured":"Brenner, D. J. & Hall, E. J. Computed tomography\u2013an increasing source of radiation exposure. N. Engl. J. Med. 357, 2277\u20132284 (2007).","journal-title":"N. Engl. J. Med."},{"key":"509_CR35","doi-asserted-by":"crossref","unstructured":"Evans, R. W. et al. Neuroimaging for migraine: the American Headache Society systematic review and evidence-based guideline. Headache 60, 318\u2013336 (2019).","DOI":"10.1111\/head.13720"},{"key":"509_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1468-1331.2010.03212.x","volume":"18","author":"G Sandrini","year":"2011","unstructured":"Sandrini, G. et al. Neurophysiological tests and neuroimaging procedures in non-acute headache (2nd edition). Eur. J. Neurol. 18, 373\u2013381 (2011).","journal-title":"Eur. J. Neurol."},{"key":"509_CR37","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/jamainternmed.2014.173","volume":"174","author":"BC Callaghan","year":"2014","unstructured":"Callaghan, B. C., Kerber, K. A., Pace, R. J., Skolarus, L. E. & Burke, J. F. Headaches and neuroimaging: high utilization and costs despite guidelines. JAMA Intern. Med. 174, 819\u2013821 (2014).","journal-title":"JAMA Intern. Med."},{"key":"509_CR38","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/head.13057","volume":"57","author":"RW Evans","year":"2017","unstructured":"Evans, R. W. Incidental findings and normal anatomical variants on MRI of the brain in adults for primary headaches. Headache 57, 780\u2013791 (2017).","journal-title":"Headache"},{"key":"509_CR39","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/head.13588","volume":"59","author":"RB Lipton","year":"2019","unstructured":"Lipton, R. B. et al. Unmet acute treatment needs from the 2017 Migraine in America Symptoms and Treatment Study. Headache 59, 1310\u20131323 (2019).","journal-title":"Headache"},{"key":"509_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10194-011-0298-4","volume":"12","author":"SB Munksgaard","year":"2011","unstructured":"Munksgaard, S. B. et al. What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information? J. Headache Pain 12, 91\u201396 (2011).","journal-title":"J. Headache Pain"},{"key":"509_CR41","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp, Z. et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35, 478\u2013488 (2015).","journal-title":"Cephalalgia"},{"key":"509_CR42","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/head.12464","volume":"54","author":"RB Lipton","year":"2014","unstructured":"Lipton, R. B., Pavlovic, J. M., Haut, S. R., Grosberg, B. M. & Buse, D. C. Methodological issues in studying trigger factors and premonitory features of migraine. Headache 54, 1661\u20131669 (2014).","journal-title":"Headache"},{"key":"509_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-018-0734-0","volume":"22","author":"MJ Marmura","year":"2018","unstructured":"Marmura, M. J. Triggers, protectors, and predictors in episodic migraine. Curr. Pain Headache Rep. 22, 81 (2018).","journal-title":"Curr. Pain Headache Rep."},{"key":"509_CR44","unstructured":"World Health Organization. Atlas of headache disorders and resources in the world 2011 (WHO, 2011)."},{"key":"509_CR45","first-page":"CD008041","volume":"4","author":"V Kirthi","year":"2013","unstructured":"Kirthi, V., Derry, S. & Moore, R. A. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 4, CD008041 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR46","first-page":"CD008039","volume":"4","author":"R Rabbie","year":"2013","unstructured":"Rabbie, R., Derry, S. & Moore, R. A. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 4, CD008039 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR47","first-page":"CD008783","volume":"2","author":"S Derry","year":"2012","unstructured":"Derry, S., Rabbie, R. & Moore, R. A. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2, CD008783 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR48","first-page":"CD008040","volume":"4","author":"S Derry","year":"2013","unstructured":"Derry, S. & Moore, R. A. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 4, CD008040 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1468-2982.2008.01546.x","volume":"28","author":"PJ Goadsby","year":"2008","unstructured":"Goadsby, P. J. et al. Early vs. non-early intervention in acute migraine \u2013 \u2018Act when Mild (AwM)\u2019. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 28, 383\u2013391 (2008).","journal-title":"Cephalalgia"},{"key":"509_CR50","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/0333102411433042","volume":"32","author":"M Lant\u00e9ri-Minet","year":"2012","unstructured":"Lant\u00e9ri-Minet, M., Mick, G. & Allaf, B. Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia 32, 226\u2013235 (2012).","journal-title":"Cephalalgia"},{"key":"509_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1468-2982.2003.00554.x","volume":"23","author":"M F\u00e4rkkil\u00e4","year":"2003","unstructured":"F\u00e4rkkil\u00e4, M. et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 23, 463\u2013471 (2003).","journal-title":"Cephalalgia"},{"key":"509_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1468-2982.2005.01010.x","volume":"26","author":"CGH Dahl\u00f6f","year":"2006","unstructured":"Dahl\u00f6f, C. G. H. Infrequent or non-response to oral sumatriptan does not predict response to other triptans\u2013review of four trials. Cephalalgia 26, 98\u2013106 (2006).","journal-title":"Cephalalgia"},{"key":"509_CR53","first-page":"CD009108","volume":"5","author":"CJ Derry","year":"2014","unstructured":"Derry, C. J., Derry, S. & Moore, R. A. Sumatriptan (all routes of administration) for acute migraine attacks in adults \u2013 overview of Cochrane reviews. Cochrane Database Syst. Rev. 2014 5, CD009108 (2014).","journal-title":"Cochrane Database Syst. Rev. 2014"},{"key":"509_CR54","first-page":"CD008541","volume":"4","author":"S Law","year":"2016","unstructured":"Law, S., Derry, S. & Moore, R. A. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst. Rev. 4, CD008541 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR55","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJM199108013250504","volume":"325","author":"[No authors listed]","year":"1991","unstructured":"[No authors listed] Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N. Engl. J. Med. 325, 316\u2013321 (1991).","journal-title":"N. Engl. J. Med."},{"key":"509_CR56","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton, R. B. et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N. Engl. J. Med. 381, 142\u2013149 (2019).","journal-title":"N. Engl. J. Med."},{"key":"509_CR57","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton, R. B. et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322, 1887\u20131898 (2019).","journal-title":"JAMA"},{"key":"509_CR58","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby, P. J. et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142, 1894\u20131904 (2019).","journal-title":"Brain"},{"key":"509_CR59","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1468-2982.2008.01578.x","volume":"28","author":"PC Tfelt-Hansen","year":"2008","unstructured":"Tfelt-Hansen, P. C. & Koehler, P. J. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 28, 877\u2013886 (2008).","journal-title":"Cephalalgia"},{"key":"509_CR60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.pain.2009.01.013","volume":"142","author":"ME Bigal","year":"2009","unstructured":"Bigal, M. E. & Lipton, R. B. Excessive opioid use and the development of chronic migraine. Pain 142, 179\u2013182 (2009).","journal-title":"Pain"},{"key":"509_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco, S. et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain 20, 6 (2019).","journal-title":"J. Headache Pain"},{"key":"509_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen, L. et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J. Headache Pain 19, 91 (2018).","journal-title":"J. Headache Pain"},{"key":"509_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212785","volume":"14","author":"JL Jackson","year":"2019","unstructured":"Jackson, J. L. et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS ONE 14, e0212785 (2019).","journal-title":"PLoS ONE"},{"key":"509_CR64","first-page":"CD010610","volume":"6","author":"M Linde","year":"2013","unstructured":"Linde, M., Mulleners, W. M., Chronicle, E. P. & McCrory, D. C. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst. Rev. 6, CD010610 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.289.1.65","volume":"289","author":"E Tronvik","year":"2003","unstructured":"Tronvik, E., Stovner, L. J., Helde, G., Sand, T. & Bovim, G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289, 65\u201369 (2003).","journal-title":"JAMA"},{"key":"509_CR66","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/0333102413515348","volume":"34","author":"LJ Stovner","year":"2014","unstructured":"Stovner, L. J. et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 34, 523\u2013532 (2014).","journal-title":"Cephalalgia"},{"key":"509_CR67","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/j.pain.0000000000001456","volume":"160","author":"A Stubberud","year":"2019","unstructured":"Stubberud, A., Flaaen, N. M., McCrory, D. C., Pedersen, S. A. & Linde, M. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain 160, 762\u2013772 (2019).","journal-title":"Pain"},{"key":"509_CR68","doi-asserted-by":"publisher","first-page":"C5222","DOI":"10.1136\/bmj.c5222","volume":"341","author":"JL Jackson","year":"2010","unstructured":"Jackson, J. L. et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 341, C5222 (2010).","journal-title":"BMJ"},{"key":"509_CR69","first-page":"CD010611","volume":"6","author":"M Linde","year":"2013","unstructured":"Linde, M., Mulleners, W. M., Chronicle, E. P. & McCrory, D. C. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst. Rev. 6, CD010611 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0898-3","volume":"19","author":"E Vatzaki","year":"2018","unstructured":"Vatzaki, E. et al. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. J. Headache Pain 19, 68 (2018).","journal-title":"J. Headache Pain"},{"key":"509_CR71","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.clinthera.2009.03.020","volume":"31","author":"DW Dodick","year":"2009","unstructured":"Dodick, D. W. et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin. Ther. 31, 542\u2013559 (2009).","journal-title":"Clin. Ther."},{"key":"509_CR72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","volume":"51","author":"JR Couch","year":"2011","unstructured":"Couch, J. R. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 51, 33\u201351 (2011).","journal-title":"Headache"},{"key":"509_CR73","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/jnnp-2018-320113","volume":"90","author":"U Reuter","year":"2019","unstructured":"Reuter, U., McClure, C., Liebler, E. & Pozo-Rosich, P. Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. J. Neurol. Neurosurg. Psychiatry 90, 796\u2013804 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"509_CR74","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s00415-016-8126-z","volume":"263","author":"A Sullivan","year":"2016","unstructured":"Sullivan, A., Cousins, S. & Ridsdale, L. Psychological interventions for migraine: a systematic review. J. Neurol. 263, 2369\u20132377 (2016).","journal-title":"J. Neurol."},{"key":"509_CR75","first-page":"CD001218","volume":"2016","author":"K Linde","year":"2016","unstructured":"Linde, K. et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst. Rev. 2016, CD001218 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR76","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1474-4422(06)70382-9","volume":"5","author":"H-C Diener","year":"2006","unstructured":"Diener, H.-C. et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. Lancet 5, 310\u2013316 (2006).","journal-title":"Lancet"},{"key":"509_CR77","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1177\/0333102415597889","volume":"36","author":"K Luedtke","year":"2016","unstructured":"Luedtke, K., Allers, A., Schulte, L. H. & May, A. Efficacy of interventions used by physiotherapists for patients with headache and migraine-systematic review and meta-analysis. Cephalalgia 36, 474\u2013492 (2016).","journal-title":"Cephalalgia"},{"key":"509_CR78","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.13836","volume":"60","author":"NA Hindiyeh","year":"2020","unstructured":"Hindiyeh, N. A. et al. The role of diet and nutrition in migraine triggers and treatment: a systematic literature review. Headache 60, 1300\u20131316 (2020).","journal-title":"Headache"},{"key":"509_CR79","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11916-006-0047-6","volume":"10","author":"ME Bigal","year":"2006","unstructured":"Bigal, M. E. & Lipton, R. B. Migraine at all ages. Curr. Pain Headache Rep. 10, 207\u2013213 (2006).","journal-title":"Curr. Pain Headache Rep."},{"key":"509_CR80","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1212\/01.wnl.0000225186.76323.69","volume":"67","author":"ME Bigal","year":"2006","unstructured":"Bigal, M. E., Liberman, J. N. & Lipton, R. B. Age-dependent prevalence and clinical features of migraine. Neurology 67, 246\u2013251 (2006).","journal-title":"Neurology"},{"key":"509_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11916-011-0196-0","volume":"15","author":"CC Bamford","year":"2011","unstructured":"Bamford, C. C., Mays, M. & Tepper, S. J. Unusual headaches in the elderly. Curr. Pain Headache Rep. 15, 295\u2013301 (2011).","journal-title":"Curr. Pain Headache Rep."},{"key":"509_CR82","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1177\/0333102414560635","volume":"35","author":"K Vongvaivanich","year":"2015","unstructured":"Vongvaivanich, K., Lertakyamanee, P., Silberstein, S. D. & Dodick, D. W. Late-life migraine accompaniments: a narrative review. Cephalalgia 35, 894\u2013911 (2015).","journal-title":"Cephalalgia"},{"key":"509_CR83","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/head.13749","volume":"60","author":"H-C Diener","year":"2020","unstructured":"Diener, H.-C. The risks or lack thereof of migraine treatments in vascular disease. Headache 60, 649\u2013653 (2020).","journal-title":"Headache"},{"key":"509_CR84","unstructured":"World Health Organization. Prevention of Cardiovascular Disease: Guidelines for assessment and management of cardiovascular risk (WHO, 2007)."},{"key":"509_CR85","first-page":"0318","volume":"2015","author":"NP Barnes","year":"2015","unstructured":"Barnes, N. P. Migraine headache in children. BMJ Clin. Evid. 2015, 0318 (2015).","journal-title":"BMJ Clin. Evid."},{"key":"509_CR86","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1474-4422(09)70303-5","volume":"9","author":"AD Hershey","year":"2010","unstructured":"Hershey, A. D. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 9, 190\u2013204 (2010).","journal-title":"Lancet Neurol."},{"key":"509_CR87","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1212\/WNL.0000000000008095","volume":"93","author":"M Oskoui","year":"2019","unstructured":"Oskoui, M. et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 93, 487\u2013499 (2019).","journal-title":"Neurology"},{"key":"509_CR88","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1212\/WNL.0000000000008105","volume":"93","author":"M Oskoui","year":"2019","unstructured":"Oskoui, M. et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 93, 500\u2013509 (2019).","journal-title":"Neurology"},{"key":"509_CR89","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1468-2982.2008.01752.x","volume":"29","author":"S Evers","year":"2009","unstructured":"Evers, S., Marziniak, M., Frese, A. & Gralow, I. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia 29, 436\u2013444 (2009).","journal-title":"Cephalalgia"},{"key":"509_CR90","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/pch\/pxx170","volume":"22","author":"AJ Faber","year":"2017","unstructured":"Faber, A. J., Lagman-Bartolome, A. M. & Rajapakse, T. Drugs for the acute treatment of migraine in children and adolescents. Paediatr. Child Health 22, 454\u2013458 (2017).","journal-title":"Paediatr. Child Health"},{"key":"509_CR91","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41582-018-0042-7","volume":"14","author":"SL Orr","year":"2018","unstructured":"Orr, S. L. et al. Paediatric migraine: evidence-based management and future directions. Nat. Rev. Neurol. 14, 515\u2013527 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"509_CR92","first-page":"CD005220","volume":"4","author":"L Richer","year":"2016","unstructured":"Richer, L. et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst. Rev. 4, CD005220 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR93","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/bmj.39559.675891.AD","volume":"336","author":"PJ Goadsby","year":"2008","unstructured":"Goadsby, P. J., Goldberg, J. & Silberstein, S. D. Migraine in pregnancy. BMJ 336, 1502\u20131504 (2008).","journal-title":"BMJ"},{"key":"509_CR94","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrneurol.2015.29","volume":"11","author":"S Amundsen","year":"2015","unstructured":"Amundsen, S., Nordeng, H., Nezvalov\u00e1-Henriksen, K., Stovner, L. J. & Spigset, O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat. Rev. Neurol. 11, 209\u2013219 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"509_CR95","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/jama.2013.278343","volume":"310","author":"B Pasternak","year":"2013","unstructured":"Pasternak, B., Svanstr\u00f6m, H., M\u00f8lgaard-Nielsen, D., Melbye, M. & Hviid, A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA 310, 1601\u20131611 (2013).","journal-title":"JAMA"},{"key":"509_CR96","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11916-011-0212-4","volume":"15","author":"KG Vetvik","year":"2011","unstructured":"Vetvik, K. G. & Russell, M. B. Are menstrual and nonmenstrual migraine attacks different? Curr. Pain Headache Rep. 15, 339\u2013342 (2011).","journal-title":"Curr. Pain Headache Rep."},{"key":"509_CR97","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0333102413507637","volume":"34","author":"KG Vetvik","year":"2014","unstructured":"Vetvik, K. G., Macgregor, E. A., Lundqvist, C. & Russell, M. B. Prevalence of menstrual migraine: a population-based study. Cephalalgia 34, 280\u2013288 (2014).","journal-title":"Cephalalgia"},{"key":"509_CR98","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1526-4610.2001.111006248.x","volume":"41","author":"L Newman","year":"2001","unstructured":"Newman, L. et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 41, 248\u2013256 (2001).","journal-title":"Headache"},{"key":"509_CR99","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1517\/14656566.2014.947959","volume":"15","author":"S Silberstein","year":"2014","unstructured":"Silberstein, S. & Patel, S. Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment. Expert Opin. Pharmacother. 15, 2063\u20132070 (2014).","journal-title":"Expert Opin. Pharmacother."},{"key":"509_CR100","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40262-017-0614-5","volume":"57","author":"SC van Dijkman","year":"2018","unstructured":"van Dijkman, S. C., de Jager, N. C. B., Rauw\u00e9, W. M., Danhof, M. & Della Pasqua, O. Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials. Clin. Pharmacokinet. 57, 1039\u20131053 (2018).","journal-title":"Clin. Pharmacokinet."},{"key":"509_CR101","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein, S. D. et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology 78, 1337\u20131345 (2012).","journal-title":"Neurology"},{"key":"509_CR102","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1468-2982.2008.01786.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton, R. B. et al. Validity and reliability of the migraine-treatment optimization questionnaire. Cephalalgia 29, 751\u2013759 (2009).","journal-title":"Cephalalgia"},{"key":"509_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0842-6","volume":"19","author":"TJ Steiner","year":"2018","unstructured":"Steiner, T. J. et al. The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. J. Headache Pain 19, 15 (2018).","journal-title":"J. Headache Pain"},{"key":"509_CR104","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10194-011-0320-x","volume":"12","author":"TJ Steiner","year":"2011","unstructured":"Steiner, T. J. et al. Recommendations for headache service organisation and delivery in Europe. J. Headache Pain 12, 419\u2013426 (2011).","journal-title":"J. Headache Pain"},{"key":"509_CR105","unstructured":"World Health Organization. Building the economic case for primary health care: a scoping review. Technical series on primary health care (WHO, 2018)."},{"key":"509_CR106","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211\u20131259 (2017).","journal-title":"Lancet"},{"key":"509_CR107","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/ene.14268","volume":"27","author":"HC Diener","year":"2020","unstructured":"Diener, H. C. et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur. J. Neurol. 27, 1102\u20131116 (2020).","journal-title":"Eur. J. Neurol."},{"key":"509_CR108","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/jnnp-2014-308548","volume":"86","author":"ES Kristoffersen","year":"2015","unstructured":"Kristoffersen, E. S. et al. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J. Neurol. Neurosurg. Psychiatry 86, 505\u2013512 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"509_CR109","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00415-015-7975-1","volume":"263","author":"ES Kristoffersen","year":"2016","unstructured":"Kristoffersen, E. S. et al. Brief intervention by general practitioners for medication-overuse headache, follow-up after 6 months: a pragmatic cluster-randomised controlled trial. J. Neurol. 263, 344\u2013353 (2016).","journal-title":"J. Neurol."},{"key":"509_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-10","volume":"15","author":"JTF Lai","year":"2014","unstructured":"Lai, J. T. F. et al. Should we educate about the risks of medication overuse headache? J. Headache Pain 15, 10 (2014).","journal-title":"J. Headache Pain"},{"key":"509_CR111","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/brain\/awz052","volume":"142","author":"JA Pijpers","year":"2019","unstructured":"Pijpers, J. A. et al. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain 142, 1203\u20131214 (2019).","journal-title":"Brain"},{"key":"509_CR112","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaneurol.2020.1179","volume":"77","author":"LN Carlsen","year":"2020","unstructured":"Carlsen, L. N. et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol. 77, 1069\u20131078 (2020).","journal-title":"JAMA Neurol."},{"key":"509_CR113","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse, D. C. et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52, 1456\u20131470 (2012).","journal-title":"Headache"},{"key":"509_CR114","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nrneurol.2012.13","volume":"8","author":"H-C Diener","year":"2012","unstructured":"Diener, H.-C. et al. Chronic migraine \u2014 classification, characteristics and treatment. Nat. Rev. Neurol. 8, 162\u2013171 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"509_CR115","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.13459","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse, D. C., Greisman, J. D., Baigi, K. & Lipton, R. B. Migraine progression: a systematic review. Headache 59, 306\u2013338 (2019).","journal-title":"Headache"},{"key":"509_CR116","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1212\/WNL.0000000000004112","volume":"89","author":"K Probyn","year":"2017","unstructured":"Probyn, K. et al. Prognostic factors for chronic headache: a systematic review. Neurology 89, 291\u2013301 (2017).","journal-title":"Neurology"},{"key":"509_CR117","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/0333102419883355","volume":"40","author":"J Xu","year":"2019","unstructured":"Xu, J., Kong, F. & Buse, D. C. Predictors of episodic migraine transformation to chronic migraine: a systematic review and meta-analysis of observational cohort studies. Cephalalgia 40, 503\u2013516 (2019).","journal-title":"Cephalalgia"},{"key":"509_CR118","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton, R. B. et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84, 688\u2013695 (2015).","journal-title":"Neurology"},{"key":"509_CR119","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1526-4610.2009.01508.x","volume":"49","author":"S Silberstein","year":"2009","unstructured":"Silberstein, S. et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49, 1153\u20131162 (2009).","journal-title":"Headache"},{"key":"509_CR120","first-page":"CD011616","volume":"6","author":"CP Herd","year":"2018","unstructured":"Herd, C. P. et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst. Rev. 6, CD011616 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"509_CR121","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles, A. & Pozo-Rosich, P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394, 1765\u20131774 (2019).","journal-title":"Lancet"},{"key":"509_CR122","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter, U. et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392, 2280\u20132287 (2018).","journal-title":"Lancet"},{"key":"509_CR123","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari, M. D. et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394, 1030\u20131040 (2019).","journal-title":"Lancet"},{"key":"509_CR124","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ene.14114","volume":"27","author":"DD Ruff","year":"2020","unstructured":"Ruff, D. D. et al. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Eur. J. Neurol. 27, 609\u2013618 (2020).","journal-title":"Eur. J. Neurol."},{"key":"509_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0988-x","volume":"20","author":"T Dresler","year":"2019","unstructured":"Dresler, T. et al. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J. Headache Pain 20, 51 (2019).","journal-title":"J. Headache Pain"},{"key":"509_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0649-2","volume":"17","author":"C Lampl","year":"2016","unstructured":"Lampl, C. et al. Headache, depression and anxiety: associations in the Eurolight project. J. Headache Pain 17, 59 (2016).","journal-title":"J. Headache Pain"},{"key":"509_CR127","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/head.13435","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse, D. C. et al. Sleep disorders among people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59, 32\u201345 (2019).","journal-title":"Headache"},{"key":"509_CR128","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/ejp.1176","volume":"22","author":"S Ashina","year":"2018","unstructured":"Ashina, S. et al. Increased pain sensitivity in migraine and tension-type headache coexistent with low back pain: A cross-sectional population study. Eur. J. Pain 22, 904\u2013914 (2018).","journal-title":"Eur. J. Pain"},{"key":"509_CR129","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/0333102414535110","volume":"35","author":"S Ashina","year":"2015","unstructured":"Ashina, S. et al. Prevalence of neck pain in migraine and tension-type headache: a population study. Cephalalgia 35, 211\u2013219 (2015).","journal-title":"Cephalalgia"},{"key":"509_CR130","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse, D. C., Manack, A., Serrano, D., Turkel, C. & Lipton, R. B. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J. Neurol. Neurosurg. Psychiatry 81, 428\u2013432 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"509_CR131","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1212\/01.wnl.0000225052.35019.f9","volume":"67","author":"ME Bigal","year":"2006","unstructured":"Bigal, M. E. & Lipton, R. B. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 67, 252\u2013257 (2006).","journal-title":"Neurology"},{"key":"509_CR132","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1212\/WNL.0b013e3181ab2c20","volume":"73","author":"T Kurth","year":"2009","unstructured":"Kurth, T., Sch\u00fcrks, M., Logroscino, G. & Buring, J. E. Migraine frequency and risk of cardiovascular disease in women. Neurology 73, 581\u2013588 (2009).","journal-title":"Neurology"},{"key":"509_CR133","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/0333102412469740","volume":"33","author":"MLS Westergaard","year":"2013","unstructured":"Westergaard, M. L. S. et al. The headache under-response to treatment (HURT) questionnaire: assessment of utility in headache specialist care. Cephalalgia 33, 245\u2013255 (2013).","journal-title":"Cephalalgia"},{"key":"509_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-16","volume":"14","author":"M Al Jumah","year":"2013","unstructured":"Al Jumah, M. et al. HURT (Headache Under-Response to Treatment) questionnaire in the management of primary headache disorders: reliability, validity and clinical utility of the Arabic version. J. Headache Pain 14, 16 (2013).","journal-title":"J. Headache Pain"},{"key":"509_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-S1-P201","volume":"14","author":"R Lipton","year":"2013","unstructured":"Lipton, R., Manack, A., Serrano, D. & Buse, D. Acute treatment optimization for migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. J. Headache Pain 14, P201 (2013).","journal-title":"J. Headache Pain"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00509-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00509-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00509-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T22:06:31Z","timestamp":1675461991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00509-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":135,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["509"],"URL":"https:\/\/doi.org\/10.1038\/s41582-021-00509-5","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"assertion":[{"value":"7 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K. has been an invited speaker for Novartis. H.-C.D. has received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from Alder, Allergan, Amgen, Electrocore, Ipsen, Lilly, Medtronic, Novartis, Pfizer, Teva and Weber & Weber. Electrocore has provided financial support for his research projects. The German research council (DFG), the German ministry of Education and Research\u00a0(BMBF) and the European Union support his headache research. He also serves on the editorial boards of <i>Cephalalgia<\/i> and <i>Lancet Neurology<\/i>, chairs the clinical guidelines committee of the German Society of Neurology and is a member of the Clinical Trials Committee of the International Headache Society. D.D.M. has received honoraria, research and travel grants from Allergan, Amgen, Biogen, Cefaly, Eli Lilly, Electrocore, Mertz, Novartis, Roche, Sanofi, Specifar and Teva. A.J.S. reports personal fees from Allergan and Novartis, grants from Novartis, and grants and personal fees from Invex Therapeutics. He is a trustee of the board of the International Headache Society and a member of the Council of the European Headache Federation. P.P.-R. has received honoraria as a consultant and speaker for Allergan, Almirall, Biohaven, Chiesi, Eli Lilly, Medlink, Medscape, Neurodiem, Novartis and Teva. Her research group has received research grants from Allergan, AGAUR, la Caixa foundation, EraNET Neuron, FEDER RISC3CAT, Migraine Research Foundation, Instituto Investigaci\u00f3n Carlos III, MICINN, Novartis and PERIS, and has received funding for clinical trials from Alder, Amgen, Electrocore, Eli Lilly, Novartis and Teva. She is the founder of www.midolordecabeza.org, a trustee of the board of the International Headache Society and a member of the Council of the European Headache Federation. She is on the editorial board of <i>Revista de Neurologia<\/i>, an associate editor for <i>Cephalalgia<\/i>, <i>Frontiers of Neurology<\/i> and <i>Journal of Headache and Pain<\/i>. She is also a member of the Clinical Trials Guidelines Committee of the International Headache Society and has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. P.M. has served on advisory boards for Allergan, Lilly, Novartis and Teva. He has received royalties from Springer Nature and travel support from the European Medicines Agency, and serves as Editor-in-Chief for <i>Journal of Headache and Pain<\/i>. A.D. reports consultant fees from Eli Lilly, Novartis and Teva. She also serves as President of the French Headache Society. M.L.-M. reports personal fees for advisory boards, speaker panels or investigation studies from Allergan, Amgen, Astellas, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, GlaxoSmithKline, Grunenthal, Lilly, Medtronic, Menarini, MSD, Novartis, Pfizer, ReckittBenckiser, Saint-Jude, Sanofi-Aventis, Teva, UCB and Zambon. M.S.d.R. reports consultant fees as a speaker or participation on advisory boards from Allergan, Eli-Lilly, Novartis and Teva. G.M.T. reports consultant fees from Amgen, Eli Lilly, Novartis and Teva, and has received grant support from the Dutch Brain Foundation, Dutch Heart Foundation, NIH, NOW and ZonMW. K.P. has received honoraria as a speaker and\/or consultant, and\/or received research support from Allergan, Amgen\/Novartis, Autonomic Technologies, Eli-Lilly and Teva. S.S. reports fees as a speaker or consultant for Allergan, Abbott, Eli-Lilly, Novartis and Teva. She is also an associate editor for <i>Stroke<\/i> and serves as co-editor for <i>Journal of Headache and Pain<\/i>. U.R. has received consulting fees, speaking or teaching fees and\/or research grants from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore and Novartis. H.W.S. has received consultant fees for lectures from Eli-Lilly, Novartis and TEVA. He has received consultant fees for advisory board participation from Balancair and Eli Lilly, and has received funding from Novartis. Z.K. has been a speaker and\/or consultant, and\/or received research support from Allergan, Amgen\/Novartis, Ely-Lilly, Merck and Teva. T.J.S. reports personal fees from Eli Lilly. M.A. has received personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Eli-Lilly, Novartis and Teva. He has been or is currently a principal investigator on clinical trials for Alder, Amgen, ElectroCore, Novartis and Teva. He serves as Associate Editor of <i>Cephalalgia<\/i>, <i>Headache<\/i> and <i>Journal of Headache and Pain<\/i>. He also reports research grants from Lundbeck Foundation, Novo Nordisk Foundation, and Research Foundation of the Capital Region of Denmark. The other authors report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}